New Trial Alert: Alliance A062102 Multiple Myeloma

April 4, 2024

Alliance A062102: Randomized phase 2 study of iberdomide maintenance therapy following idecaptagene vicleucel CAR-T in multiple myeloma patients

Overview: Alliance investigator Sascha Tuchman, MD, of UNC Lineberger Comprehensive Cancer Center, leads this phase II trial that compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleuc

Call for Nominations: Co-Chair, Alliance Publications Committee

January 30, 2024

Konstantin Dragnev, MD, will step down as Co-Chair of the Alliance Publications Committee to transition into his new role as Co-Chair of the Alliance Prevention Committee. Dr. Dragnev, a Professor of Medicine in the Department of Hematology/Oncology at Dartmouth Hitchcock Medical Center, has served in this role since 2015. Alliance wishes to extend our deepest appreciation to Dr. Dragnev for his

Alliance Study Shows Positive Results For Patients with Muscle-Invasive Urothelial Carcinoma

January 25, 2024

Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. The Alliance for Clinical Trials in Oncology today announced positive results from the phase III AMBASSADOR (A031501) trial for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced urothelial

Older News